Clinical trials: CVA
Dysphagia, Stroke
Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia
The aim of the trial is to identify any systematic effect of cohesiveness on the efficacy of swallowing in patients having dysphagia problems.
- Trial name
- NCT02522351
- Testing
- Cereal extract concentration 1, Cereal extract concentration 2, Cereal extract concentration 3
- Where
- 2 sites in Belgium, France
- Volunteers
- 35 people
- Sponsor
- Société des Produits Nestlé (SPN)
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Heart Failure
Necklace-Shaped Sensor for Non-Invasive Monitoring of Stroke Volume and Cardiac Output
Study will compare measurements made with Necklace device for stroke volume/cardiac output with values from a FDA-approved reference device. The gold standard that will be used is Cardiac MRI.
- Trial name
- NCT02719301
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Baxter Healthcare Corporation
Acute Ischemic Stroke
DAISe 1 Feasibility Study to Evaluate the DAISe Thrombectomy System for Acute Ischemic Stroke
The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 36 subjects. The maximum enrollment is 10 subjects per site. A maximum of 6 investigational centers in Europe will participate.
- Trial name
- NCT05139147
- Testing
- DAISe Thrombectomy System
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- MIVI Neuroscience, Inc.
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in STROke Recovery
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAEStro (NCT05046106)
- Testing
- MLC1501
- Volunteers
- 540 people
- Sponsor
- Moleac Pte Ltd.
Cerebral Stroke
CERENOVUS Neurothrombectomy Devices Registry
A post-market registry evaluating the EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC™ Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter in acute ischemic stroke patients with confirmed…
- Trial name
- EXCELLENT (NCT03685578)
- Testing
- EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter, CEREGLIDE 71 Intermediate Catheter
- Where
- 40 sites in United States, Belgium and 5 more
- Volunteers
- 2,000 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Stroke Volume
Electric Impedance Tomography
Evaluation of electrical impedance tomography to non-invasively monitor stroke volume when compared to reference measurements performed via right heart thermodilution
- Trial name
- SVEIT (NCT02639468)
- Testing
- Stroke Volume estimation using electrical impedance tomography
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Muscle Spasticity
Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity
Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity.
- Trial name
- NCT02757404
- Testing
- Ultrasonography guidance injection of Meditoxin®., Electrical stimulation guidance injection of Meditoxin®., Manual needle placement injection of Meditoxin®.
- Volunteers
- 59 people
- Sponsor
- Medy-Tox
Cerebrovascular Stroke
Sub-Acute Stroke Rehabilitation With AMES
The AMES device is designed to produce functional cortical changes by:(1) assisting the subject as he/she attempts to move the limb (assisted movement) and (2) enhancing movement sensation by vibrating the muscles during movement…
- Trial name
- AMES (NCT00609115)
- Testing
- AMES device (test), AMES device (crossover)
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- AMES Technology
Acute Ischemic Stroke
AXIS 2: AX200 for the Treatment of Ischemic Stroke
The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.
- Trial name
- AXIS-2 (NCT00927836)
- Testing
- Filgrastim, Sodium chloride solution
- Where
- 58 sites in Austria, Belgium and 5 more
- Volunteers
- 328 people
- Sponsor
- Sygnis Bioscience GmbH & Co KG
Nonvalvular Atrial Fibrillation
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled…
- Trial name
- NCT00684307
- Testing
- AZD0837, Vitamin-K antagonist at INR 2-3
- Volunteers
- 1,084 people
- Sponsor
- AstraZeneca
Ischemic Stroke
The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)
This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned…
- Trial name
- BQ5 (NCT05044507)
- Testing
- BQ 2.0
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- BrainQ Technologies Ltd.
Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.
- Trial name
- NCT01510184
- Testing
- Zevalin, Y-90-Zevalin, Rituximab
- Where
- 93 sites in United States, Australia and 11 more
- Volunteers
- 79 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Stroke
Validation of Neurokeeper's Algorithm on Patients Undergoing Cardiac Surgery.
The primary objective of the study is to check the ability of Neurokeeper's algorithm system to detect and monitor changes in cerebral electrophysiological parameters as compared to clinical evaluation in patients undergoing…
- Trial name
- NCT01737749
- Testing
- Neurokeeper stroke detector
- Where
- Israel
- Sponsor
- Neurokeeper Technologies
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO)
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
- Trial name
- 4-NiVO (NCT07357285)
- Testing
- Thromboaspiration catheter
- Where
- 11 sites in Germany, Hungary and 1 more
- Volunteers
- 57 people
- Sponsor
- iVascular S.L.U.
Heart Failure
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood…
- Trial name
- FINEARTS-HF (NCT04435626)
- Testing
- Finerenone (BAY94-8862)
- Where
- 661 sites in United States, Argentina and 35 more
- Volunteers
- 6,016 people
- Sponsor
- Bayer
Depression
Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects
This is a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation in depressed human subjects study.
- Trial name
- NCT01520649
- Testing
- NSI-189 Phosphate, microcrystalline cellulose capsules
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Neuralstem Inc.
Non-Valvular Atrial Fibrillation
A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
Atrial fibrillation is a heart condition that causes an abnormal and fast heart rate. For people with non-valvular atrial fibrillation (NVAF), this is caused by problems such as high blood pressure and diabetes.
- Trial name
- BELANCE (NCT04722679)
- Testing
- Non-VKA Oral Anticoagulants (NOAC)
- Where
- Belgium
- Volunteers
- 103 people
- Sponsor
- Bayer
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Acute Ischemic Stroke
Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke
This is a 3-arm, prospective, randomized, double-blind, and controlled clinical study, with 3 months of treatment to evaluate efficacy of DLBS1033 in bleeding profile and clinical outcome in patients with acute ischemic stroke…
- Trial name
- NCT01790997
- Testing
- DLBS1033, Aspirin, Clopidogrel
- Where
- Indonesia
- Volunteers
- 126 people
- Sponsor
- Dexa Medica Group